Hodgkin lymphoma version 1.2017, NCCN Clinical Practice Guidelines in Oncology Journal Article

  


Authors: Hoppe, R. T.; Advani, R. H.; Ai, W. Z.; Ambinder, R. F.; Aoun, P.; Bello, C. M.; Benitez, C. M.; Bernat, K.; Bierman, P. J.; Blum, K. A.; Chen, R.; Dabaja, B.; Forero, A.; Gordon, L. I.; Hernandez-Ilizaliturri, F. J.; Hochberg, E. P.; Huang, J.; Johnston, P. B.; Kaminski, M. S.; Kenkre, V. P.; Khan, N.; Maloney, D. G.; Mauch, P. M.; Metzger, M.; Moore, J. O.; Morgan, D.; Moskowitz, C. H.; Mulroney, C.; Poppe, M.; Rabinovitch, R.; Seropian, S.; Smith, M.; Winter, J. N.; Yahalom, J.; Burns, J.; Ogba, N.; Sundar, H.
Article Title: Hodgkin lymphoma version 1.2017, NCCN Clinical Practice Guidelines in Oncology
Abstract: This portion of the NCCN Guidelines for Hodgkin lymphoma (HL) focuses on the management of classical HL. Current management of classical HL involves initial treatment with chemotherapy or combined modality therapy followed by restaging with PET/CT to assess treatment response using the Deauville criteria (5-point scale). The introduction of less toxic and more effective regimens has significantly advanced HL cure rates. However, long-term follow-up after completion of treatment is essential to determine potential long-term effects. © JNCCN-Journal of the National Comprehensive Cancer Network.
Journal Title: Journal of the National Comprehensive Cancer Network
Volume: 15
Issue: 5
ISSN: 1540-1405
Publisher: Harborside Press  
Date Published: 2017-05-01
Start Page: 608
End Page: 638
Language: English
PROVIDER: scopus
PUBMED: 28476741
DOI: 10.6004/jnccn.2017.0064
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85019066211&partnerID=40&md5=88f4fa5004aa044732699642af5850d2
Notes: Review -- Export Date: 2 June 2017 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Joachim Yahalom
    625 Yahalom
  2. Craig Moskowitz
    407 Moskowitz
Related MSK Work